



Prior Authorization Request

PRALUENT (alirocumab)

Instructions

Please complete Part A and have your physician complete Part B. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. Please note that you have the right to appeal the decision made by Express Scripts Canada.

Part A – Patient

Patient information

First Name:		Last Name:	
Insurance Carrier Name/Number:			
Group Number:		Client ID:	
Date of Birth (YYYY/MM/DD):		Relationship: <input type="checkbox"/> Employee <input type="checkbox"/> Spouse <input type="checkbox"/> Dependent	
Language: <input type="checkbox"/> English <input type="checkbox"/> French		Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female	
Address:			
City:	Province:	Postal Code:	
Email address:			
Telephone (home):	Telephone (cell):	Telephone (work):	

Coordination of benefits

Patient Assistance Program	Is the patient enrolled in any patient assistance program? <input type="checkbox"/> Yes <input type="checkbox"/> No Contact Name: _____ Fax: _____
Provincial Coverage	Has the patient applied for reimbursement under a provincial plan? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A What is the coverage decision of the drug? <input type="checkbox"/> Approved <input type="checkbox"/> Denied <i>*Attach decision letter*</i>
Primary Coverage	Has the patient applied for reimbursement under a primary plan? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A What is the coverage decision of the drug? <input type="checkbox"/> Approved <input type="checkbox"/> Denied <i>*Attach decision letter*</i>

Authorization

On behalf of myself and my eligible dependents, I authorize my group benefit provider, and its agents, to exchange the personal information contained on this form. I give my consent on the understanding that the information will be used solely for purposes of administration and management of my group benefit plan. This consent shall continue so long as my dependents and I are covered by, or are claiming benefits under the present group contract, or any modification, renewal, or reinstatement thereof.

Plan Member Signature

Date



Prior Authorization Request

PRALUENT (alirocumab)

Part B – Prescriber

Please see instructions on page 1 and complete all sections below. Incomplete forms may result in automatic denial. Please do not provide genetic test information or results.

SECTION 1 – DRUG REQUESTED

PRALUENT (alirocumab) <input type="checkbox"/> New request <input type="checkbox"/> Renewal request*			
Dose	Administration (ex: oral, IV, etc)	Frequency	Duration
Site of drug administration:			
<input type="checkbox"/> Home	<input type="checkbox"/> Physician's office/Infusion clinic	<input type="checkbox"/> Hospital (outpatient)	<input type="checkbox"/> Hospital (inpatient)

* Please submit proof of prior coverage if available

SECTION 2 – ELIGIBILITY CRITERIA

1. Please indicate if the patient satisfies the below criteria:

Atherosclerotic Cardiovascular Disease

INITIAL

- For the treatment of clinical atherosclerotic cardiovascular disease (ASCVD) in an adult defined by one of the following: ischemic heart disease (angina, history of heart attack), cerebrovascular disease (stroke), and/or peripheral vascular disease/peripheral arterial disease, AND
- The patient is taking one moderate-to-high intensity statin or has a documented intolerance to at least 2 statins (*Please list prior therapies in the chart below*), AND
- The patient has had an inadequate response or has a documented intolerance or contraindication to ezetimibe, AND
- The patient's LDL-C level is 1.8 mmol/L or greater, or non-HDL-C level is 2.4 mmol/L or greater, or Apo-B level is 0.7 g/L or greater, despite taking a maximally tolerated statin dose. Please indicate at least one of the patient's lipid parameter levels below:

Date (YYYY-MM-DD)	LDL-C (mmol/L)	non-HDL-C (mmol/L)	Apo-B (g/L)

RENEWAL

- The patient has demonstrated LDL-C, non-HDL-C, or Apo-B reduction to target. Please indicate at least one of the patient's baseline and current lipid parameter levels below:

BASELINE			
Date (YYYY-MM-DD)	LDL-C (mmol/L)	non-HDL-C (mmol/L)	Apo-B (g/L)

CURRENT			
Date (YYYY-MM-DD)	LDL-C (mmol/L)	non-HDL-C (mmol/L)	Apo-B (g/L)



Prior Authorization Request

PRALUENT (alirocumab)

Primary Hyperlipidemia

INITIAL

- For the treatment of primary hyperlipidemia including heterozygous familial hypercholesterolemia (HeFH) and non-familial hypercholesterolemia in an adult unable to reach target LDL-C levels, AND
- The patient is currently receiving a maximally-tolerated dose of statin therapy (*Please list prior therapies in the chart below*), OR
- The patient has a documented intolerance or contraindication to at least two different statins (*Please list prior therapies in the chart below*), AND
- The patient has had an inadequate response or has a documented intolerance or contraindication to ezetimibe, AND
- The patient's LDL-C level is 2 mmol/L or greater despite current therapy, OR
- The patient has not achieved a 50% reduction in LDL-C from pre-treatment levels despite current therapy, OR
- The patient's non-HDL-C level is 2.4 mmol/L or greater, or Apo-B level is 0.7 g/L or greater despite current therapy. Please indicate at least one of the patient's lipid parameter levels below:

Date (YYYY-MM-DD)	LDL-C (mmol/L)	non-HDL-C (mmol/L)	Apo-B (g/L)

RENEWAL

- The patient has demonstrated LDL-C, non-HDL-C, or Apo-B reduction to target. Please indicate at least one of the patient's baseline and current lipid parameter levels below:

BASELINE			
Date (YYYY-MM-DD)	LDL-C (mmol/L)	non-HDL-C (mmol/L)	Apo-B (g/L)

CURRENT			
Date (YYYY-MM-DD)	LDL-C (mmol/L)	non-HDL-C (mmol/L)	Apo-B (g/L)

OR

- None of the above criteria applies.

Relevant additional information:

Prior Authorization Request

PRALUENT (alirocumab)

2. Please list previously tried therapies

Drug	Dosage and administration	Duration of therapy		Reason for cessation	
		From	To	Inadequate response	Allergy/Intolerance
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>

SECTION 3 – PRESCRIBER INFORMATION

Physician's Name:	
Address:	
Tel:	Fax:
License No.:	Specialty:
Physician Signature: _____ Date: _____	

Please fax or mail the completed form to Express Scripts Canada®

Fax: Express Scripts Canada Clinical Services
1 (855) 712-6329

Mail: Express Scripts Canada Clinical Services
6985 Financial Drive, Suite 300
Mississauga, ON, L5N 0G3